Randomized Trial of Patiromer on Efficacy to Reduce Episodic Hyperkalemia in Patients with ESKD Treated With Hemodialysis

Introduction: Individuals with end-stage kidney disease (ESKD) maintained on hemodialysis (HD) carry a high risk of cardiac arrhythmias. This risk is heightened by episodic hyperkalemia. The purpose of the study was to investigate whether patiromer administered daily reduced episodes of hyperkalemia...

Description complète

Détails bibliographiques

Auteurs principaux:	John P. Middleton, Shifeng Sun, Susan Murray, Clemontina A. Davenport, James P. Daubert
Format:	Artigo
Langue:	Inglês
Publié:	Elsevier 2024-11-01
Collection:	Kidney International Reports
Sujets:	cardiac arrhythmia cardiovascular risk clinical trial hemodialysis hyperkalemia
Accès en ligne:	http://www.sciencedirect.com/science/article/pii/S2468024924018771
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!